275 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
2 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
3 Completed Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
Conditions: Breast Cancer;   Metastatic Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: temozolomide
4 Withdrawn A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
Condition: Lymphoma, B-Cell
Interventions: Drug: bendamustine;   Drug: navitoclax;   Drug: rituximab
5 Active, not recruiting Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Tecemotide;   Drug: Placebo;   Drug: Cyclophosphamide (CPA);   Drug: Saline (sodium chloride)
6 Completed A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: bevacizumab [Avastin];   Drug: irinotecan;   Drug: temozolomide
7 Recruiting Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Conditions: Hematopoietic/Lymphoid Cancer;   Nausea and Vomiting;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Olanzapine;   Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin);   Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant);   Other: Placebo
8 Recruiting Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Biological: ofatumumab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography with radiolabeled targeting agents;   Radiation: fludeoxyglucose F 18
9 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
10 Recruiting Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate;   Drug: bortezomib;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: melphalan;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Other: laboratory biomarker analysis
11 Recruiting Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Conditions: Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor
Interventions: Drug: Indoximod;   Drug: Temozolomide
12 Recruiting Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.
Condition: Glioblastoma
Intervention: Drug: Temozolomide
13 Recruiting A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma
Condition: Glioma
Interventions: Radiation: Radiotherapy;   Drug: bevacizumab [Avastin];   Drug: temozolomide (TMZ)
14 Active, not recruiting Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   L1 Adult Acute Lymphoblastic Leukemia;   L2 Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: dasatinib;   Drug: cytarabine;   Drug: methotrexate;   Biological: filgrastim;   Drug: methylprednisolone;   Drug: leucovorin calcium;   Drug: prednisone;   Radiation: total-body irradiation;   Drug: etoposide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis
15 Recruiting Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myelogenous Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: G-CSF;   Biological: Interleukin-2;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Rituximab;   Biological: Natural killer cell therapy;   Biological: T-cell depleted HPC transplant;   Biological: CD45RA-depleted HPC transplant
16 Active, not recruiting Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions: Drug: Idelalisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Fludarabine;   Drug: Everolimus;   Drug: Bortezomib;   Drug: Chlorambucil;   Drug: Lenalidomide
17 Active, not recruiting Veliparib and Temozolomide in Treating Patients With Acute Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   B-cell Adult Acute Lymphoblastic Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: temozolomide;   Drug: veliparib;   Other: pharmacological study;   Other: laboratory biomarker analysis
18 Active, not recruiting Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Conditions: Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: trastuzumab;   Drug: tamoxifen citrate;   Drug: aromatase inhibition therapy
19 Recruiting Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
Condition: Metastatic Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Metronomic Cyclophosphamide
20 Not yet recruiting An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma
Condition: Childhood Ependymoma
Interventions: Drug: 16 weeks of VEC + CDDP;   Drug: VEC + HD-MTX;   Drug: Chemotherapy + Valproate;   Radiation: Conformal radiotherapy;   Drug: VEC;   Drug: Chemotherapy;   Radiation: conformal radiotherapy +/- boost

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years